<DOC>
	<DOC>NCT02101125</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of concomitant administration of BMS-986020 on the single dose Pharmacokinetics (PK) of Rosuvastatin in healthy subjects.</brief_summary>
	<brief_title>Drug Interaction Study With Rosuvastatin</brief_title>
	<detailed_description />
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Healthy subjects who have no clinically significant deviation from normal in medical history, surgical history, PE, vital signs, ECG, and clinical laboratory determinations Nonsmokers Body Mass Index (BMI) of 18.0 to 32.0 kg/m2, inclusive. Men, ages 18 to 50 years, inclusive Men and women, ages 18 to 50 years, inclusive Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of investigational product Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) (11 days) plus 5 halflives of the study drug (4 days) plus 90 days (duration of sperm turnover) for a total of 94 days posttreatment completion Any significant acute or chronic medical illness Current or recent (within 3 months of study drug administration) gastrointestinal disease Any major surgery within 4 weeks of study drug administration Any gastrointestinal surgery (eg, partial gastrectomy, pyloroplasty) including cholecystectomy that could impact upon the absorption of study drug Donation of &gt; 400 mL of blood within 8 weeks or donation of plasma (except at screening visit) within 4 weeks of study drug administration Blood transfusion within 4 weeks of study drug administration Inability to tolerate oral medication Inability to be venipunctured and/or tolerate venous access as determined by the investigator Use of tobaccocontaining or nicotine containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to checkin, or a positive nicotine test (ie, cotinine) at screening or checkin Subjects who drink more than 3 cups of coffee or other caffeine containing products with an equivalent amount of caffeine per day, or 5 cups of tea per day History of allergy to Lysophosphatidic acid (LPA1) antagonists or related compounds</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>